$SLXN
Silexion Therapeutics Corp Stock $slxn

$slxn Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000117891324003686 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$170.0K
YoY Change			-29.17%
% of Gross Profit
Research & Development		$3.217M	$535.0K
YoY Change		501.31%
% of Gross Profit
Depreciation & Amortization		$22.00K	$10.00K
YoY Change		120.0%
% of Gross Profit
Operating Expenses		$8.036M	$160.0K
YoY Change		4922.5%	-30.43%
Operating Profit		-$8.036M	-$731.0K
YoY Change		999.32%
Interest Expense			$230.0K
YoY Change			-55.77%
% of Operating Profit
Other Income/Expense, Net		$3.822M	$72.00K
YoY Change		5208.33%
Pretax Income		-$11.86M	$70.00K
YoY Change		-17040.0%	-75.86%
Income Tax		$2.000K	$6.000K
% Of Pretax Income			8.57%
Net Earnings		-$11.86M	$70.00K
YoY Change		-17042.86%	-75.86%
Net Earnings / Revenue
Basic Earnings Per Share		$2.03	$0.78
Diluted Earnings Per Share		$2.03	$0.01
COMMON SHARES
Basic Shares Outstanding	14.43B shares	9.768M shares	1.006M shares
Diluted Shares Outstanding		5.828M shares	1.006M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$5.600M
YoY Change		-95.17%
Cash & Equivalents	$1.973M	$100.0K
Short-Term Investments		$5.600M
Other Short-Term Assets	$80.00K	$0.00
YoY Change		-100.0%
Inventory
Prepaid Expenses	$944.0K
Receivables
Other Receivables
Total Short-Term Assets	$3.047M	$5.700M
YoY Change	-46.54%	-95.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$35.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$40.00K	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$3.047M	$5.700M
Total Long-Term Assets	$40.00K	$0.00
Total Assets	$3.087M	$5.700M
YoY Change	-45.84%	-95.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$799.0K	$0.00
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.583M	$2.500M
YoY Change	43.32%	150.0%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$0.00
YoY Change
Total Long-Term Liabilities	$4.083M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.583M	$2.500M
Total Long-Term Liabilities	$4.083M	$0.00
Total Liabilities	$7.666M	$2.500M
YoY Change	206.64%	150.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.58M
YoY Change
Common Stock	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.579M	$3.100M
YoY Change
Total Liabilities & Shareholders Equity	$3.087M	$5.700M
YoY Change	-45.84%	-95.09%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$11.86M	$70.00K
YoY Change	-17042.86%	-75.86%
Depreciation, Depletion And Amortization	$22.00K	$10.00K
YoY Change	120.0%
Cash From Operating Activities	-$2.653M	-$30.00K
YoY Change	8743.33%	-108.33%
INVESTING ACTIVITIES
Capital Expenditures	$16.00K	$6.000K
YoY Change	166.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$16.00K	$72.00K
YoY Change	-122.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$22.15M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.920M	-21.77M
YoY Change	-113.41%	-6320.0%
NET CHANGE
Cash From Operating Activities	-$2.653M	-30.00K
Cash From Investing Activities	-$16.00K	$72.00K
Cash From Financing Activities	$2.920M	-21.77M
Net Change In Cash	$251.0K	-21.80M
YoY Change	-101.15%	-3170.42%
FREE CASH FLOW
Cash From Operating Activities	-$2.653M	-$30.00K
Capital Expenditures	$16.00K	$6.000K
Free Cash Flow	-$2.669M	-$36.00K
YoY Change	7313.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	slxn	Stock Issued During Period Value Issuance Of Ordinary Shares Upon Transactions StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponTransactions		usd
CY2024Q3	slxn	Stock Issued During Period Value Issuance Of Ordinary Shares Upon Transactions StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponTransactions		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0002022416
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40073
	dei	Entity Registrant Name EntityRegistrantName	SILEXION THERAPEUTICS CORP
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Address Address Line1 EntityAddressAddressLine1	12 Abba Hillel Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ramat-Gan
	dei	Entity Address Country EntityAddressCountry	IL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	5250606
	dei	City Area Code CityAreaCode	+972
	dei	Local Phone Number LocalPhoneNumber	8-6286005
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14427814000	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1973000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4595000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	25000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	944000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	335000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	80000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	24000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	3047000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4979000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	25000	usd
CY2024Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	5000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	5000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	40000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	277000	usd
CY2024Q3	us-gaap	Assets Assets	3087000	usd
CY2023Q4	us-gaap	Assets Assets	5256000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	799000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	319000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	112000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	200000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	687000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	207000	usd
CY2024Q3	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1858000	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1358000	usd
CY2024Q3	slxn	Private Warrant To Purchase Ordinary Shares PrivateWarrantToPurchaseOrdinaryShares	10000	usd
CY2023Q4	slxn	Private Warrant To Purchase Ordinary Shares PrivateWarrantToPurchaseOrdinaryShares	0	usd
CY2024Q3	slxn	Underwriters Promissory Notes Current Liabilities UnderwritersPromissoryNotesCurrentLiabilities	229000	usd
CY2023Q4	slxn	Underwriters Promissory Notes Current Liabilities UnderwritersPromissoryNotesCurrentLiabilities	0	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3583000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2196000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	59000	usd
CY2024Q3	slxn	Underwriters Promissory Notes Non Current Liabilities UnderwritersPromissoryNotesNonCurrentLiabilities	977000	usd
CY2023Q4	slxn	Underwriters Promissory Notes Non Current Liabilities UnderwritersPromissoryNotesNonCurrentLiabilities	0	usd
CY2024Q3	slxn	Promissory Notes To Related Parties PromissoryNotesToRelatedParties	3106000	usd
CY2023Q4	slxn	Promissory Notes To Related Parties PromissoryNotesToRelatedParties	0	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4083000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	59000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	7666000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2255000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	0	usd
CY2023Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	15057000	usd
CY2024Q3	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	0	usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	3420000	usd
CY2024Q3	us-gaap	Preferred Stock Redemption Amount PreferredStockRedemptionAmount	0	usd
CY2023Q4	us-gaap	Preferred Stock Redemption Amount PreferredStockRedemptionAmount	18477000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11180031	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11180031	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	873665	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	873665	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	37003000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11335000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41583000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26811000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4579000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-15476000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4579000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3001000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3087000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5256000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4944000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2451000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3217000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	535000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5727000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	502000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4819000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	196000	usd
	us-gaap	Operating Expenses OperatingExpenses	10671000	usd
	us-gaap	Operating Expenses OperatingExpenses	2953000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	8036000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	731000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10671000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2953000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8036000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-731000	usd
	slxn	Financial Expenses FinancialExpenses	4092000	usd
	slxn	Financial Expenses FinancialExpenses	449000	usd
CY2024Q3	slxn	Financial Expenses FinancialExpenses	3822000	usd
CY2023Q3	slxn	Financial Expenses FinancialExpenses	72000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14763000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3402000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11858000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-803000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14772000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3428000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-11860000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-809000	usd
	slxn	Equity Holders Of The Company EquityHoldersOfTheCompany	14696000	usd
	slxn	Equity Holders Of The Company EquityHoldersOfTheCompany	3214000	usd
CY2024Q3	slxn	Equity Holders Of The Company EquityHoldersOfTheCompany	11851000	usd
CY2023Q3	slxn	Equity Holders Of The Company EquityHoldersOfTheCompany	787000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	76000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	214000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	22000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14772000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3428000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-11860000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-809000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.6
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.6
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.2
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.2
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.03
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.03
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.78
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2622655	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2622655	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1005531	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1005531	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5828109	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5828109	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1005531	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1005531	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7567000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	412000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	96000	usd
	us-gaap	Profit Loss ProfitLoss	-3428000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4647000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3001000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5862000	usd
	slxn	Stock Issued During Period Value Issuance Of Convertible Preferred Shares Net Exercise Of Warrants StockIssuedDuringPeriodValueIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants	334000	usd
	us-gaap	Profit Loss ProfitLoss	-14772000	usd
	slxn	Conversion Of Convertible Preferred Shares And Non Controlling Interest Share Issued Value ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue	0	usd
	slxn	Stock Issued During Period Value Issuance Of Ordinary Shares For Eloc Holders StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders	996000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4579000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5424000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	32000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-809000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4647000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	153000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5798000	usd
CY2024Q3	slxn	Stock Issued During Period Value Issuance Of Convertible Preferred Shares Net Exercise Of Warrants StockIssuedDuringPeriodValueIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants	334000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-11860000	usd
CY2024Q3	slxn	Conversion Of Convertible Preferred Shares And Non Controlling Interest Share Issued Value ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue	0	usd
CY2024Q3	slxn	Stock Issued During Period Value Issuance Of Ordinary Shares For Eloc Holders StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders	996000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4579000	usd
	us-gaap	Profit Loss ProfitLoss	-14772000	usd
	us-gaap	Profit Loss ProfitLoss	-3428000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-11860000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-809000	usd
	us-gaap	Depreciation Depreciation	37000	usd
	us-gaap	Depreciation Depreciation	39000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	22000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	10000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5862000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	96000	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	5798000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	32000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	3968000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	365000	usd
CY2024Q3	us-gaap	Other Noncash Expense OtherNoncashExpense	3749000	usd
CY2023Q3	us-gaap	Other Noncash Expense OtherNoncashExpense	108000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1000	usd
CY2024Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1000	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-68000	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
CY2024Q3	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-68000	usd
CY2023Q3	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	609000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	200000	usd
CY2024Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	417000	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	198000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	59000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-15000	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	17000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-24000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	479000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	74000	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	517000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	131000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-40000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7000	usd
CY2024Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-44000	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	480000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-75000	usd
CY2024Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	436000	usd
CY2023Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-13000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-884000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-150000	usd
CY2024Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-905000	usd
CY2023Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	33000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5470000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3272000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2653000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-685000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	507000	usd
CY2024Q3	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
CY2023Q3	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000	usd
CY2024Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	usd
CY2023Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	78000	usd
CY2024Q3	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023Q3	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	78000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	577000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	72000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	522000	usd
CY2024Q3	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	620000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	620000	usd
CY2023Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	2300000	usd
	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	usd
CY2024Q3	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	2300000	usd
CY2023Q3	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2920000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	522000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2920000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2572000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2173000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	251000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-613000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-50000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-324000	usd
CY2024Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25000	usd
CY2023Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-66000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4645000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8309000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1747000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6491000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2023000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5812000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2023000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5812000	usd
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1973000	usd
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5764000	usd
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1973000	usd
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5764000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	48000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	48000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2023000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5812000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2023000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5812000	usd
	slxn	Operating Lease Termination OperatingLeaseTermination	55000	usd
	slxn	Operating Lease Termination OperatingLeaseTermination	0	usd
CY2024Q3	slxn	Operating Lease Termination OperatingLeaseTermination	55000	usd
CY2023Q3	slxn	Operating Lease Termination OperatingLeaseTermination	0	usd
	slxn	Conversion Of Preferred Shares ConversionOfPreferredShares	15058000	usd
	slxn	Conversion Of Preferred Shares ConversionOfPreferredShares	0	usd
CY2024Q3	slxn	Conversion Of Preferred Shares ConversionOfPreferredShares	15058000	usd
CY2023Q3	slxn	Conversion Of Preferred Shares ConversionOfPreferredShares	0	usd
	slxn	Conversion Of Warrants To Preferred Shares On A Cashless Basis ConversionOfWarrantsToPreferredSharesOnACashlessBasis	334000	usd
	slxn	Conversion Of Warrants To Preferred Shares On A Cashless Basis ConversionOfWarrantsToPreferredSharesOnACashlessBasis	0	usd
CY2024Q3	slxn	Conversion Of Warrants To Preferred Shares On A Cashless Basis ConversionOfWarrantsToPreferredSharesOnACashlessBasis	334000	usd
CY2023Q3	slxn	Conversion Of Warrants To Preferred Shares On A Cashless Basis ConversionOfWarrantsToPreferredSharesOnACashlessBasis	0	usd
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3344000	usd
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2024Q3	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3344000	usd
CY2023Q3	slxn	Conversion Of Warrants To Preferred Shares On A Cashless Basis ConversionOfWarrantsToPreferredSharesOnACashlessBasis	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	25000	usd
	us-gaap	Interest Paid Net InterestPaidNet	120000	usd
CY2024Q3	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet	42000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<div> <div style="line-height:1.25;font-weight:bold;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1 - GENERAL:</span></span></div> <div> <div> <div style="line-height:1.25;font-weight:bold"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Silexion Therapeutics Corp (“New Silexion”) (hereinafter -"the Company" or the “combined company”) is a newly formed entity that was formed for the purpose of effecting the Transactions (see below), and now serves as a publicly-traded holding company of its subsidiaries — including Moringa Acquisition Corp (“Moringa” or “the SPAC”), a Cayman Islands exempted company and Silexion Therapeutics Ltd. (formerly known as Silenseed Ltd.) (“Silexion”), an Israeli limited company— after the closing of the Transactions (the “Closing”).</span></span></div> </div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div style="font-weight:normal"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial Information Presented:</span></span></div> <div style="line-height:1.25"> </div> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">From its formation on April 2, 2024 until the consummation of the Transactions on August 15, 2024, the Company had no operations and had been formed for the sole purpose of entering into the Transactions and serving as the publicly-traded company following the Transactions. Silexion, on the other hand, as the accounting acquirer in the Transactions and the predecessor entity to the Company from an accounting perspective, had active operations during earlier periods of time, prior to the Transactions. Consequently, these financial statements reflect the information of Silexion (as the predecessor entity to the Company) until August 15, 2024 and the information of New Silexion (as the combined company following the Transactions) from that date forward.</span></span></div> </div> </div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div style="font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiaries:</span></span></div> <div style="font-weight:normal"> </div> <div style="font-weight:normal"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has three subsidiaries as of September 30, 2024:</span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"> </div> </div> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:69.5pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Silenseed (China) Ltd.</span> On April 28, 2021, Silexion (as the predecessor entity to the Company) signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (“GIBF”) to establish a new company in China. On June 15, 2021 a company was established in China, named Silenseed (China) Ltd. (hereinafter - the "Subsidiary"). As of September 30, 2024, following transfer of all interests in the Subsidiary to the Company as part of the Transactions, the Company owns (directly or indirectly) 100% of the shares of the Subsidiary. The Subsidiary has no significant operations as of September 30, 2024 (see Note c).</span></span></div> </div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:69.5pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Moringa</span>. Prior to the Transactions, Moringa’s class A ordinary shares and warrants were listed for trading on the Nasdaq Capital Market (Nasdaq: MACA and MACAW). As part of the Transactions, Moringa merged with a wholly-owned subsidiary of the Company and now serves as an inactive, wholly-owned subsidiary of the Company.</span></span></div> </div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:69.5pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Silexion</span>. Silexion was incorporated in Israel and began its operations on November 30, 2008. Since its incorporation, Silexion has been engaged in one operating segment - the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop the production of a specific pancreatic cancer-causing protein known as the KRAS mutation. Silexion’s long-lived assets are located in Israel.</span></span></div> </div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:69.5pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company, the Subsidiary, Moringa and Silexion are together referred to hereinafter as “the Group”.</span></span></div> </div> </td> </tr> </table> </div> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:auto;vertical-align:top;text-align:justify"> <div> </div> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">d.</td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 3, 2024, Silexion entered into an Amended and Restated Business Combination Agreement (hereinafter, “A&R BCA”) with the SPAC, New Silexion, August M.S. Ltd. an Israeli company and wholly-owned subsidiary of New Silexion (“Merger Sub 1”), and Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and wholly-owned subsidiary of New Silexion (“Merger Sub 2”). Under the A&R BCA, both Silexion and the SPAC were toi become wholly-owned subsidiaries of New Silexion, which was to become a publicly-held, Nasdaq-listed entity (the A&R BCA and related transactions: the “Transactions”).</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 15, 2024, the parties completed the Transactions pursuant to which Merger Sub 2 merged with and into the SPAC, with the SPAC continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the “SPAC Merger”), and Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the “Acquisition Merger”).</span></span></div> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Upon the effectiveness of the SPAC Merger, each outstanding SPAC Class A ordinary share and the sole outstanding SPAC Class B ordinary share was converted into an ordinary share of New Silexion on a one-for-one basis. Each outstanding warrant to purchase one SPAC Class A ordinary share was converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price. Upon the effectiveness of the Acquisition Merger, each outstanding ordinary share and each outstanding preferred share of Silexion was converted into 3.9829 shares of New Silexion (the “Silexion Equity Exchange Ratio”). Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted share unit (RSU) that may be potentially settled for one Silexion share, was to become exercisable for, or became subject to settlement for (as applicable), such number of New Silexion ordinary shares as were equal to the Silexion Equity Exchange Ratio. The exercise price per New Silexion ordinary share of each such converted Silexion option and Silexion warrant was to be adjusted based on dividing the existing per share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and RSUs were to remain the same following such conversion, except that the vesting of each Silexion option was to accelerate immediately prior to the Acquisition Merger, such that the New Silexion option into which it was to be converted was to be fully vested, and all Silexion warrants were to be exercised (on a cashless basis) immediately prior to the Acquisition Merger.</span></span></div> <div style="text-align:justify;line-height:1.25"> </div> <div></div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Immediately prior to the Closing seven directors were elected to New Silexion’s board of directors, of whom five were designated by Silexion and two were designated by the SPAC’s sponsor (the “Sponsor”).</span></span></div> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The A&R BCA also required, as a closing condition, the transfer of the remaining outstanding shares of the Subsidiary held by GIBF to Silexion prior to the closing of the Business Combination in exchange for the issuance to GIBF of shares of Silexion, which were to be converted into ordinary shares of New Silexion in accordance with the Silexion Equity Exchange Ratio upon the closing.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the closing of the Transactions, the ordinary shares and warrants of New Silexion are now listed on the Nasdaq Global Market and began trading under the symbols “SLXN” and “SLXNW”, respectively.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For more information on instruments issued as part of the Transactions, see Note 3.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;color:rgb(0, 0, 0)"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span>g.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div> <div style="line-height:1.25"><span style="font-size:10pt"><span>The Transactions were accounted for as a reverse recapitalization in accordance with US GAAP. Under this method of accounting, Silexion was treated as the accounting acquirer and the SPAC was treated as the “acquired” company for financial reporting purposes. Silexion was determined to be the accounting acquirer based on evaluation of the following facts and circumstances:</span></span></div> </div> </td> </tr> </table> </div> <div> <div> <div style="line-height:1.25"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"> </div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:93pt;text-indent:-21pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">• Silexion’s shareholders were to hold approximately 61.55% of the outstanding voting interests in New Silexion upon the closing of the Transactions;</span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:93pt;text-indent:-21pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">• Silexion’s senior management were to comprise the senior management of New Silexion;</span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:93pt;text-indent:-21pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">• the directors nominated by Silexion were to constitute a majority of the board of directors of New Silexion (five out of seven of the initial directors);</span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:93pt;text-indent:-21pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">• Silexion’s operations were to comprise the ongoing operations of New Silexion; and</span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:93pt;text-indent:-21pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">• Silexion’s name was to be the name used by New Silexion (in replacement of Biomotion Sciences).</span></span></div> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the reverse recapitalization accounting method, the Transactions were deemed to be the equivalent of a capital transaction in which Silexion issued shares for the net assets of the SPAC. The net assets of the SPAC were stated at fair value, with no goodwill or other intangible assets recorded. Operations prior to the Transactions are those of Silexion.</span></span></div> </div> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with the applicable guidance to reverse recapitalization, the equity structure has been retroactively adjusted in all comparative periods up to the date of the Closing (the “Closing Date”), to reflect the number of New Silexion’s Ordinary Shares, $0.0001 par value per share issued to legacy Silexion shareholders in connection with the reverse recapitalization transaction. As such, the shares and corresponding capital amounts and earnings per share related to legacy Silexion shareholders prior to the reverse recapitalization have been retroactively restated as shares reflecting the exchange ratio established pursuant to the Transactions. In conjunction with the reverse recapitalization, Silexion’s Ordinary Shares underwent a 1-for-3.9829 conversion.</span></span></div> </div> </div> </div> <div style="line-height:1.25"> </div> <div></div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In parallel, there have been continued hostilities along Israel’s northern border, as the Hezbollah terrorist organization based in Lebanon has conducted rocket, drone, and, more recently, missile attacks against Israel. The hostilities with Hezbollah have escalated recently, prompting Israel to send its ground forces into southern Lebanon to destroy terrorist positions and infrastructure used by Hezbollah for attacks on northern and central Israel, which had caused the displacement of residents in northern Israel since early in the war. There have also been rocket, drone and missile attacks against Israel by the Houthi movement in Yemen and from Iran. </span></span></div> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s headquarters are located in the central region of Israel. As of the issuance date of these consolidated financial statements, these conflicts have not had a material impact on the Company’s results of operations or financial position, if at all. The Company cannot currently predict the intensity or duration of Israel’s war, however, as most of the Company’s trials are not executed in Israel, the Company does not believe the recent terrorist attack and the subsequent escalation will have any material impact on its ongoing operations. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Any hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely affect the Company’s operations and results of operations and could make it more difficult for the Company to raise capital.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Going concern:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since its inception, the Company (and, prior to the Transactions, its predecessor, Silexion) has devoted substantially all its efforts to research and development, clinical trials, and capital raising activities. The Company is still in its development and clinical stage and has not yet generated revenues.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company (or, for those periods prior to the Transactions, its predecessor, Silexion) has incurred losses of $14,772 and $5,108 for the nine-months period ended on September 30, 2024 and for the year ended December 31, 2023, respectively. During the nine-month period ended on September 30, 2024, the Company (including Silexion, for periods prior to the Transactions) had negative operating cash flows of $5,470. As of September 30, 2024, the Company had cash and cash equivalents of $1,973. On August 15, 2024, Silexion completed a business combination with the SPAC.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating various financing alternatives, as the Company will need to finance future research and development activities, general and administrative expenses and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such funding.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under these circumstances, in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for at least 12 months from the date these financial statements are issued. The unaudited condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern (see Note 1 (d)).</span></span></div> </div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	slxn	Stock Conversion Ratio StockConversionRatio	1-for-3.9829
	us-gaap	Interest Costs Incurred InterestCostsIncurred	14772000	usd
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred	5108000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5470000	usd
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1973000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:51pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top"> <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Use of estimates</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. As applicable to these financial statements, the most significant estimates and assumptions relate share-based compensation and to fair value of financial instruments. See Note 6 and Notes 4 and 7, respectively. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span></span></div> </div>
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	25000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	25000	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	85000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.003
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.0007
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-919000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3000	usd
CY2024Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-1064000	usd
CY2023Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	52000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	47000	usd
CY2024Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	52000	usd
CY2023Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	44000	usd
	slxn	Loss Upon Entering Transactions LossUponEnteringTransactions	4783000	usd
	slxn	Loss Upon Entering Transactions LossUponEnteringTransactions	0	usd
CY2024Q3	slxn	Loss Upon Entering Transactions LossUponEnteringTransactions	4783000	usd
CY2023Q3	slxn	Loss Upon Entering Transactions LossUponEnteringTransactions	0	usd
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-25000	usd
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-120000	usd
CY2024Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	0	usd
CY2023Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-42000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	196000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	520000	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	48000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	69000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4092000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	449000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3822000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	72000	usd
CY2024Q3	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-68000	usd
CY2024Q3	slxn	Disposal Of Leasehold Improvements DisposalOfLeaseholdImprovements	18000	usd
CY2024Q3	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	10000	usd
CY2023Q2	slxn	Warrants Issued WarrantsIssued	21717	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	24.769
CY2023Q2	us-gaap	Other Expenses OtherExpenses	3000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8213	shares
	slxn	Revaluation Expenses Income RevaluationExpensesIncome	134000	usd
	slxn	Revaluation Expenses Income RevaluationExpensesIncome	40000	usd
CY2024Q3	slxn	Revaluation Expenses Income RevaluationExpensesIncome	-11000	usd
CY2023Q3	slxn	Revaluation Expenses Income RevaluationExpensesIncome	43000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5862000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	96000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	575572	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7482	pure
CY2022	slxn	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Probability Of Other Liquidation Events SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsProbabilityOfOtherLiquidationEvents	0.33	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y3M
CY2022	slxn	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Return On Equity SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedReturnOnEquity	0.22	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	485149	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.326
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M17D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	316000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	124020	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.003
	slxn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercised	P0Y3D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	490000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2928	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.724
	slxn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermForfeited	P6Y7D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	121420	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.562
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	236781	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.441
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M2D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	236781	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.441
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M2D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	236781	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.441
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y1M2D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5862000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	96000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5798000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32000	usd
	slxn	Credit Spread Percentage CreditSpreadPercentage	0.0667	pure
	us-gaap	Net Income Loss NetIncomeLoss	-14772000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3428000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-11860000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-809000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	14696000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14696000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3214000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3214000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	11851000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	11851000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	787000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	787000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2622655	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2622655	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1005531	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1005531	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5828109	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5828109	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1005531	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1005531	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.6
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.6
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.2
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.2
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.03
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.03
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.78
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.003
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.0007
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1195	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	131866	shares

Files In Submission

Name	View Source	Status
0001178913-24-003686-index-headers.html	Edgar Link	pending
0001178913-24-003686-index.html	Edgar Link	pending
0001178913-24-003686.txt	Edgar Link	pending
0001178913-24-003686-xbrl.zip	Edgar Link	pending
exhibit_31-1.htm	Edgar Link	pending
exhibit_31-2.htm	Edgar Link	pending
exhibit_32-1.htm	Edgar Link	pending
exhibit_32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slxn-20240930.xsd	Edgar Link	pending
zk2432270.htm	Edgar Link	pending
slxn-20240930_cal.xml	Edgar Link	unprocessable
slxn-20240930_def.xml	Edgar Link	unprocessable
slxn-20240930_lab.xml	Edgar Link	unprocessable
slxn-20240930_pre.xml	Edgar Link	unprocessable
zk2432270_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLXN
Silexion Therapeutics Corp Stock $slxn

2024 Q4 Form 10-Q Financial Statement

#000117891324003686 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLXN Silexion Therapeutics Corp Stock $slxn

2024 Q4 Form 10-Q Financial Statement

#000117891324003686 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLXN
Silexion Therapeutics Corp Stock $slxn